A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
Drew Rasco(Texas Oncology), Yifan Zhai(Unknown), Dajun Yang, Joan Sun, Zhiyan Liang(East China University of Science and Technology), Yuefen Tang, Alex Amaya(South Texas Accelerated Research Therapeutics), Kathy Estkowski(South Texas Accelerated Research Therapeutics), Yufeng Li(Chinese Academy of Sciences), Jiao Ji(Sun Yat-sen University), Yingjie Huang, Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), Lichuang Men, Hengbang Wang
Cited by 27
Related Papers
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
|Clinical Cancer Research|2012|432